The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Dec. 08, 2016
Applicant:

Dendropharm Gmbh, Berlin, DE;

Inventors:

Emanuel Fleige, Berlin, DE;

Sam Moré, Dresden, DE;

Michael Unbehauen, Berlin, DE;

Rainer Haag, Berlin, DE;

Christoph Stein, Berlin, DE;

Halina Machelska-Stein, Berlin, DE;

Florian Paulus, Munich, DE;

Assignee:

DendroPharm GmbH, Berlin, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/34 (2017.01); A61K 31/485 (2006.01); A61K 31/40 (2006.01); A61K 9/51 (2006.01); A61P 25/04 (2006.01); A61K 47/10 (2017.01); A61K 31/135 (2006.01); A61K 31/44 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 9/5192 (2013.01); A61K 31/40 (2013.01); A61K 31/485 (2013.01); A61K 47/10 (2013.01); A61P 25/04 (2018.01); A61K 31/135 (2013.01); A61K 31/44 (2013.01); A61K 2300/00 (2013.01);
Abstract

The invention relates to the field of analgesics. According to the invention, a kit or composition, particularly a pharmaceutical composition or a pharmaceutical kit, is provided, comprising a nanocarrier which is a hyperbranched polymer, such as a dendritic polymer or dendrimer, preferably having a molecular weight of 1,000-100,000 g/mol, and an analgesic which, when administered without nanocarrier, has both peripheral and central analgesic effect, preferably an opioid such as nalbuphine. According to the invention, the analgesic in this composition mainly or exclusively has a peripheral effect and thus reduces side effects triggered by the activation of central or intestinal opioid receptors. It is used for the treatment of peripheral pain and/or inflammation. The invention also relates to particularly suitable nanocarriers.


Find Patent Forward Citations

Loading…